查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1957249

藥品灌裝和包裝契約製造市場－全球產業規模、佔有率、趨勢、機會和預測：按產品類型、分子類型、最終用戶、地區和競爭格局分類，2021-2031年

Fill-finish Pharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Molecule Type, By End-user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球灌裝和包裝藥品的契約製造市場預計將從 2025 年的 86.1 億美元成長到 2031 年的 123.2 億美元，複合年成長率為 6.15%。

該行業細分領域涵蓋最終生產階段，包括將配製好的藥品填充到無菌容器（例如管瓶和注射器）中，並進行包裝以供商業分銷。推動成長的關鍵因素是全球對需要特殊無菌處理的生物製藥的需求不斷成長，以及製藥研發公司將這些營運外包的策略轉變。這種方式使公司能夠避免維護無菌設施相關的高昂資本成本，並將資源集中在藥物研發等核心活動，同時利用外部專業知識來完成複雜的填充流程。

市場概覽
預測期 2027-2031
市場規模：2025年 86.1億美元
市場規模：2031年 123.2億美元
複合年成長率：2026-2031年 6.15%
成長最快的細分市場 預填充式注射器
最大的市場 亞太地區

然而，該產業在應對產能限制的同時，也必須遵守嚴格的無菌保證監管標準，這構成了一項重大挑戰。擴大無菌生產線規模所面臨的複雜挑戰常常造成生產瓶頸，尤其是在高價值注射領域。根據製藥、化學及相關技術協會 (DCAT) 預測，到 2025 年，該行業正積極應對這些限制，預計將有 15 億至 20 億美元的投資用於建設大規模灌裝和包裝設施，這些設施計劃在不久的將來投入運作。這些數據凸顯了契約製造製造商在嚴格遵守品質標準的同時，快速擴展基礎設施的巨大壓力。

市場促進因素

該領域的成長主要受生物製藥和生物相似藥市場的快速擴張所驅動，尤其是對Glucagon-Like Peptide-1(GLP-1)促效劑的爆炸性需求。這些高分子量治療藥物需要高度專業化的無菌環境和溫度控制，使得許多製藥公司難以實現內部規模化生產，導致對契約製造的依賴性日益增強。這種依賴性已經發展到大型製藥公司收購契約製造以確保其供應鏈安全的程度。例如，諾和諾德 (Novo Holdings) 於 2024 年 2 月宣布，已達成一項價值 165 億美元的合併協議，收購契約製造Catalent，以確保獲得三家用於糖尿病和減肥藥的填充和包裝工廠。這一趨勢表明，生產無菌注射劑的能力正成為一項與藥物研發本身同等重要的策略性資產。

同時，預填充式注射器和先進給藥系統的日益普及，促使生產線進行重組，並需要發展更精湛的技術。製藥研發公司正從傳統的管瓶轉向以患者為中心的給藥方式，以減少給藥錯誤並提高用藥依從性，這迫使契約製造製造商投資建造專用的即用型組件填充線。這種向高附加價值給藥系統的轉變與供應商的收入成長直接相關。根據 Stevanat 集團於 2024 年 3 月發布的《2023 年第四季及全年財務業績報告》，其年收入成長 10% 至 10.9 億歐元，主要得益於高附加價值預滅菌容器解決方案的廣泛應用。為了滿足這一不斷變化的需求，FUJIFILM迪奧辛塔生物技術公司等製造商正在積極擴張。 2024 年 4 月，該公司決定追加投資 12 億美元，用於擴大其大型生物製造設施，並確保擁有足夠的基礎設施以進行複雜的無菌加工。

市場挑戰

全球灌裝包裝藥品的契約製造市場面臨一項重大挑戰：如何在嚴格遵守無菌通訊協定的同時，有效管理產能限制。儘管生物製藥的需求不斷成長，但無菌環境下複雜的驗證流程使得契約製造生產商難以快速擴大生產線規模以滿足市場需求。這種營運瓶頸限制了高價值注射劑的最終灌裝量，迫使生產商推遲計劃進度，甚至可能終止契約，從而直接限制了整體市場收入。

近期有關供應缺口的產業指標凸顯了這項限制的嚴重性。據美國醫療保健系統藥劑師協會 (ASHP) 稱，2024 年第一季，醫療保健行業經歷了創紀錄的 323 起藥品短缺事件，其中約一半與無菌注射劑相關。這些頻繁的短缺表明，目前的填充和包裝基礎設施已不堪重負，無法持續滿足商業性需求。因此，由於製造商難以調整產能以滿足全球日益成長的無菌藥品需求，市場成長受到阻礙。

市場趨勢

無手套機器人隔離器和自動化填充線的整合正在變革無菌生產。這主要源自於產業消除人為錯誤並遵守歐盟GMP附錄1等嚴格法規的需求。這些系統透過完全消除關鍵無菌區域的人員，顯著降低了污染風險，並確保了高度敏感生物製藥的更高無菌保證。契約製造製造商正積極採用這項技術，以提供更優異的合規性和營運效率。例如，根據《醫療保健包裝》雜誌2024年5月刊報道，PCI Pharma Services公司在新罕布夏州啟動了一項耗資1億美元的擴建計劃，其中包括安裝一條最先進的大型隔離器填充線。該計劃顯然旨在透過從設計階段就考慮無菌性的流程來提高高通量生產能力。

同時，市場處理高活性和細胞毒性藥物的能力正在迅速擴張，這主要得益於抗體藥物複合體（ADC）的復興。與標準生物製藥不同，這些治療方法需要專門的設施，既要確保產品的無菌性，又要嚴格保護操作人員免受毒性物質的侵害。為此，合約研發生產機構（CDMO）正在建造專用的高等級生物安全填充和包裝車間。同時，大量資金也投入專門為高活性化合物設計的基礎建設。根據LiveMint 2024年9月的報告顯示，Piramal Pharma Solutions宣布投資8,000萬美元擴建位於萊剋星頓的工廠，旨在提升其抗體藥物複合體（ADC）和其他無菌注射劑的商業化生產能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球藥品灌裝與包裝契約製造市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（預填充式注射器、管瓶、藥筒、其他）
    • 依分子類型（高分子量、低分子量）
    • 依最終用戶（製藥和生技公司、契約製造組織等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美藥品填充和包裝契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲藥品灌裝和包裝契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區藥品填充和包裝契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲藥品填充和包裝契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲藥品填充和包裝契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球藥品填充和包裝契約製造市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Pfizer Inc.
  • Baxter Pharmaceutical Solutions LLC
  • Eurofins Scientific SE
  • Symbiosis Pharma Pvt Ltd
  • MabPlex International Co. Ltd.
  • Fresenius Kabi Manufacturing
  • Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24057

The Global Fill-finish Pharmaceutical Contract Manufacturing Market is projected to expand from USD 8.61 Billion in 2025 to USD 12.32 Billion by 2031, registering a CAGR of 6.15%. This industry segment encompasses the final production stage where formulated medications are dispensed into sterile containers, such as vials or syringes, and packaged for commercial distribution. Growth is largely fueled by the rising global demand for biologics requiring specialized aseptic processing, coupled with a strategic shift among pharmaceutical developers to outsource these operations. This approach enables companies to avoid the high capital costs of maintaining sterile facilities, allowing them to redirect resources toward core competencies like drug discovery while utilizing external expertise for the complex finishing process.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.61 Billion
Market Size 2031USD 12.32 Billion
CAGR 2026-20316.15%
Fastest Growing SegmentPrefilled Syringes
Largest MarketAsia Pacific

However, the industry faces significant hurdles related to managing capacity limitations while adhering to strict regulatory standards for sterility assurance. The intricacies involved in scaling sterile manufacturing lines frequently result in bottlenecks, especially for high-value injectable therapies. According to the Drug, Chemical & Associated Technologies Association, in 2025, the sector actively addressed these constraints with major fill-finish investments estimated between $1.5 billion and $2 billion slated to become operational in the near future. This data underscores the intense pressure on contract manufacturers to rapidly broaden their infrastructure while strictly complying with rigorous quality standards.

Market Driver

The sector is primarily driven by the rapid growth of the biologics and biosimilars market, specifically the explosive demand for glucagon-like peptide-1 (GLP-1) receptor agonists. These large-molecule therapies necessitate highly specific aseptic environments and temperature controls that many pharmaceutical originators cannot scale internally, creating a heavy reliance on contract manufacturers. This dependency has escalated to the point where major pharmaceutical companies are acquiring contract organizations to ensure supply chain security; for instance, according to Novo Holdings' February 2024 press release regarding the acquisition of Catalent, the organization entered a merger agreement valued at $16.5 billion to acquire the contract manufacturer specifically to secure three fill-finish sites for its diabetes and obesity treatments. This trend suggests that manufacturing capacity for sterile injectables is becoming a strategic asset as vital as drug discovery itself.

Simultaneously, the increasing use of prefilled syringes and advanced delivery systems is reshaping production lines and necessitating technical specialization. Pharmaceutical developers are transitioning from traditional vials to patient-centric delivery formats that decrease dosing errors and enhance adherence, compelling contract manufacturers to invest in specialized filling lines for ready-to-use components. This shift toward high-value delivery systems translates directly into revenue growth for suppliers; according to Stevanato Group's 'Fourth Quarter and Full Year 2023 Financial Results' in March 2024, fiscal revenue rose 10% to €1.09 billion, driven largely by the surging adoption of high-value pre-sterilized containment solutions. To meet this evolving demand, manufacturers like Fujifilm Diosynth Biotechnologies are aggressively expanding, with the company committing an additional $1.2 billion in April 2024 to expand its large-scale biomanufacturing facility and ensure sufficient infrastructure for complex aseptic processing.

Market Challenge

The Global Fill-finish Pharmaceutical Contract Manufacturing Market faces a primary obstacle in managing capacity limitations while adhering to rigorous sterility protocols. Despite the rising demand for biological therapies, contract manufacturers frequently struggle to expand production lines rapidly enough to match this pace due to the complex validation processes required for aseptic environments. This operational bottleneck restricts the volume of high-value injectables that can be finalized, compelling manufacturers to delay project timelines and decline potential contracts, which directly constrains overall market revenue.

The severity of this constraint is highlighted by recent industry metrics concerning supply gaps. According to the American Society of Health-System Pharmacists, the healthcare sector recorded a historic high of 323 active drug shortages during the first quarter of 2024, with nearly half of these cases involving sterile injectable medications. This high frequency of shortages demonstrates that the current fill-finish infrastructure is critically strained and unable to consistently meet commercial requirements. Consequently, the market's growth is impeded as manufacturers struggle to align their output capabilities with the escalating global necessity for sterile drug products.

Market Trends

The integration of gloveless robotic isolators and automated filling lines is transforming sterile manufacturing, driven by the industry's need to eliminate human error and comply with stringent regulations such as EU GMP Annex 1. By completely removing operators from critical aseptic zones, these systems significantly lower contamination risks and ensure higher sterility assurance levels for sensitive biological products. Contract manufacturers are aggressively adopting this technology to provide superior compliance profiles and operational efficiency; for example, according to Healthcare Packaging in May 2024, PCI Pharma Services began installing a state-of-the-art, large-scale isolator filling line as part of a $100 million expansion in New Hampshire, explicitly aiming to increase high-throughput capacity with aseptic-by-design processes.

Concurrently, the market is observing a rapid expansion in capabilities for handling high-potency and cytotoxic drugs, particularly propelled by the resurgence of antibody-drug conjugates (ADCs). Unlike standard biologics, these therapies require specialized facilities that ensure both product sterility and rigorous operator protection from toxic exposure, prompting CDMOs to construct dedicated high-containment fill-finish suites. This trend involves significant capital allocation toward infrastructure designed specifically for highly active compounds; according to LiveMint in September 2024, Piramal Pharma Solutions announced an $80 million investment to expand its Lexington site, specifically to enhance its commercial manufacturing capabilities for antibody-drug conjugates and other sterile injectables.

Key Market Players

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Pfizer Inc.
  • Baxter Pharmaceutical Solutions LLC
  • Eurofins Scientific SE
  • Symbiosis Pharma Pvt Ltd
  • MabPlex International Co. Ltd.
  • Fresenius Kabi Manufacturing
  • Novartis AG

Report Scope

In this report, the Global Fill-finish Pharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fill-finish Pharmaceutical Contract Manufacturing Market, By Product Type

  • Prefilled Syringes
  • Vials
  • Cartridges
  • Others

Fill-finish Pharmaceutical Contract Manufacturing Market, By Molecule Type

  • Large Molecules
  • Small Molecules

Fill-finish Pharmaceutical Contract Manufacturing Market, By End-user

  • Pharmaceutical & Biotechnology Companies
  • Contract Manufacturing Organizations
  • Others

Fill-finish Pharmaceutical Contract Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fill-finish Pharmaceutical Contract Manufacturing Market.

Available Customizations:

Global Fill-finish Pharmaceutical Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Prefilled Syringes, Vials, Cartridges, Others)
    • 5.2.2. By Molecule Type (Large Molecules, Small Molecules)
    • 5.2.3. By End-user (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organizations, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Molecule Type
    • 6.2.3. By End-user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Molecule Type
        • 6.3.1.2.3. By End-user
    • 6.3.2. Canada Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Molecule Type
        • 6.3.2.2.3. By End-user
    • 6.3.3. Mexico Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Molecule Type
        • 6.3.3.2.3. By End-user

7. Europe Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Molecule Type
    • 7.2.3. By End-user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Molecule Type
        • 7.3.1.2.3. By End-user
    • 7.3.2. France Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Molecule Type
        • 7.3.2.2.3. By End-user
    • 7.3.3. United Kingdom Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Molecule Type
        • 7.3.3.2.3. By End-user
    • 7.3.4. Italy Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Molecule Type
        • 7.3.4.2.3. By End-user
    • 7.3.5. Spain Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Molecule Type
        • 7.3.5.2.3. By End-user

8. Asia Pacific Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Molecule Type
    • 8.2.3. By End-user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Molecule Type
        • 8.3.1.2.3. By End-user
    • 8.3.2. India Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Molecule Type
        • 8.3.2.2.3. By End-user
    • 8.3.3. Japan Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Molecule Type
        • 8.3.3.2.3. By End-user
    • 8.3.4. South Korea Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Molecule Type
        • 8.3.4.2.3. By End-user
    • 8.3.5. Australia Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Molecule Type
        • 8.3.5.2.3. By End-user

9. Middle East & Africa Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Molecule Type
    • 9.2.3. By End-user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Molecule Type
        • 9.3.1.2.3. By End-user
    • 9.3.2. UAE Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Molecule Type
        • 9.3.2.2.3. By End-user
    • 9.3.3. South Africa Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Molecule Type
        • 9.3.3.2.3. By End-user

10. South America Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Molecule Type
    • 10.2.3. By End-user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Molecule Type
        • 10.3.1.2.3. By End-user
    • 10.3.2. Colombia Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Molecule Type
        • 10.3.2.2.3. By End-user
    • 10.3.3. Argentina Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Molecule Type
        • 10.3.3.2.3. By End-user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Fill-finish Pharmaceutical Contract Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Catalent Inc.
  • 15.4. Pfizer Inc.
  • 15.5. Baxter Pharmaceutical Solutions LLC
  • 15.6. Eurofins Scientific SE
  • 15.7. Symbiosis Pharma Pvt Ltd
  • 15.8. MabPlex International Co. Ltd.
  • 15.9. Fresenius Kabi Manufacturing
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer